This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plotnikov, A. Articles by Fuchs, S. Y. Search for Related Content PubMed PubMed Citation Articles by Plotnikov, A. Articles by Fuchs, S. Y.

Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3β Impairs Degradation of Prolactin Receptor

¹ Department of Animal Biology and ² Mari Lowe Center for Comparative Oncology, University of Pennsylvania; ³ Kimmel Cancer Center, Department of Cancer Biology and ⁴ Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania

Requests for reprints: Serge Y. Fuchs, School of Veterinary Medicine, University of Pennsylvania, Room 316 Hill Pavilion, 380 S University Avenue, Philadelphia, PA 19104-4539. Phone: 215-573-6949; Fax: 215-746-2295; E-mail: syfuchs{at}vet.upenn.edu.

Key Words: prolactin receptor • ubiquitin • glycogen synthase kinase 3β • breast cancer • βTrcp

Prolactin receptors (PRLr) expressed in a majority of breast cancer are activated by prolactin and growth hormone. The PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser³⁴⁹, which, when phosphorylated, recruits the βTrcp E3 ubiquitin ligase and facilitates PRLr degradation. Here, we show that constitutive oncogenic signaling downstream of ErbB2 and Ras stabilizes PRLr via inhibitory phosphorylation of glycogen synthase kinase-3β (GSK3β) on Ser⁹. Importantly, inactivation of GSK3β correlates with elevated levels of PRLr protein in clinical human breast cancer specimens. Additional studies using pharmacologic, biochemical, and genetic approaches reveal that GSK3β is a bona fide PRLr kinase that phosphorylates PRLr on Ser³⁴⁹ and is required for the recognition of PRLr by βTrcp, as well as for PRLr ubiquitination and degradation. [Cancer Res 2008;68(5):1354–61]

This article has been cited by other articles:

				V. V. Levina, B. Nolen, Y. Su, A. K. Godwin, D. Fishman, J. Liu, G. Mor, L. G. Maxwell, R. B. Herberman, M. J. Szczepanski, et al. Biological Significance of Prolactin in Gynecologic Cancers Cancer Res., June 15, 2009; 69(12): 5226 - 5233. [Abstract] [Full Text] [PDF]

				A. Plotnikov, B. Varghese, T. H. Tran, C. Liu, H. Rui, and S. Y. Fuchs Impaired Turnover of Prolactin Receptor Contributes to Transformation of Human Breast Cells Cancer Res., April 1, 2009; 69(7): 3165 - 3172. [Abstract] [Full Text] [PDF]

				E. Beurel and R. S. Jope Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3 J. Biol. Chem., August 8, 2008; 283(32): 21934 - 21944. [Abstract] [Full Text] [PDF]